Skip to main content
. 2018 Jan 16;18:1. doi: 10.1186/s12902-017-0228-9

Table 2.

Change in metabolic parameters after treatment

Variables Metformin-insulin
n = 29
İnsulin-only
n = 29
p value
∆ Metabolic syndrome prevalence (%) −8.9 ± 1.3 2.5 ± 0.6 0.028
∆ Body weight (kg) −0.41 ± 2.44 0.13 ± 2.55 0.222
∆ Waist circumference (cm) −0.34 ± 1.67 0.41 ± 1.61 0.384
∆ FPG (mg/dl) −26.9 ± 54.2 0.7 ± 29.5 0.022
∆ PPG (mg/dl) −43.1 ± 61.8 −3.1 ± 40.1 0.010
∆ HbA1c (%) −0.8 ± 1.4 −0.3 ± 1.3 0.075
∆ Total cholesterol (mg/dl) −2.78 ± 36.7 −2.20 ± 17.9 0.962
∆ Triglycerides (mg/dl) −21.5 ± 98.6 −26.2 ± 75.5 0.855
∆ LDL-C (mg/dl) −5.0 ± 27.6 −4.9 ± 23.8 0.899
∆ HDL-C (mg/dl) 0.43 ± 9.65 2.88 ± 9.50 0.522
∆ Systolic blood pressure (mmHg) 1.55 ± 11.02 6.72 ± 6.16 0.032
∆ Diastolic blood pressure (mmHg) 0.48 ± 6.41 4.82 ± 7.84 0.025
∆ Total daily insulin dose (IU/kg bodyweight/d)a −0.03 (−0.39 ─ 0.28) 0.11 (−0.24 ─ 0.35) 0.006

Data are shown as mean ± standard deviation (means ± SD) and amedian (min-max)

The difference (∆) are shown as change in values before and after treatment (after value minus before value)

Abbreviations: FPG fasting plasma glucose, HbA1c hemoglobin A1c, PPG postprandial plasma glucose, HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, IU international units

Bold represents the significant p-values